Clinical Trial Update: Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of a live-attenuated RSV vaccine by Sanofi Pasteur to evaluate safety, transmissibility, and genetic stability of the vaccine virus among close …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV live-attenuated vaccine (Sanofi Pasteur)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Respiratory Syncytial Virus Infection | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-01-26